Plasma derived phosphoglycerate mutase 5 (PGAM5) as a biomarker for Parkinson’s disease

Liang Feng,Haijun He,Xi Xiong,Kai Xia,Shuangjie Qian,Qianqian Ye,Feifei Feng,Shuoting Zhou,Yiming Liu,Chenglong xie

DOI: https://doi.org/10.21203/rs.3.rs-1704637/v1

2022-01-01

Abstract:Abstract Background: Phosphoglycerate mutase 5 (PGAM5) regulates mitochondrial dynamics and programmed cell death, which relates to the pathogenesis of Parkinson’s disease (PD). This study aimed to examine whether plasma PGAM5 was a biomarker for PD diagnosis, and whether which was associated with the severity of motor or nonmotor manifestations of PD.Methods: Our data enrolled 124 patients of PD (PD group) and 50 healthy controls (HC group) , baseline characteristics of both groups were collected. We measured plasma PGAM5 levels with a quantitative sandwich enzyme immunoassay technique (ELISA). PD group received evaluations at baseline with the Unified Parkinson’s Disease Rating Scale (UPDRS); Mini-Mental State Examination (MMSE) score, Hamilton depression Rating Scale (HAMD), Hamilton Anxiety Rating Scale (HAMA), the Rating Scale of RBDQ-HK and Activity of Daily Living Scale (ADL) were finished both PD group and HC group. Receiver operator characteristic (ROC) curves were used to evaluate the predictive value of plasma PAMG5 alone and PAMG5 combined with other factors for PD diagnosis.Results: We found plasma PGAM5 levels were significantly higher in the patients with PD than HC groups, with an area under the curve (AUC) of 0.76. In terms of the subgroup analysis, the AUC for the elder subjects (＞60 years old) was 0.78, and for patients without hypertension was 0.79. Of note, when combined with plasma oligomeric α-synuclein (α-syn), AUC was 0.80; while combined with the score of the RBDQ-HK with an AUC of 0.82. Plasma PAMG5 levels were connected to PD independently in a multivariable logistic analysis (odds ratio,1.875 [95% CI 1.206-2.916], p=0.005), but showed no correlation with the severity of motor and other nonmotor manifestations of PD. Conclusions: Plasma PGAM5 was an independent biomarker for PD, aiding to distinguish PD from healthy controls, especially among those elder (＞60 years old) and patients without hypertension. The predictive value of PGAM5 would be elevated when combined with plasma oligomeric α-syn or the Rating Scale of RBDQ-HK.